Upfront, comprehensive genetic testing in advanced lung cancer is cost-effective

May 17, 2018, American Society of Clinical Oncology

An economic model comparing different types of genetic testing in metastatic non-small-cell lung cancer (NSCLC) found that using next-generation sequencing (NGS) to test for all known lung cancer-related gene changes at the time of diagnosis was more cost-effective and faster than testing one or a limited number of genes at a time.

The model included Medicare and with 1 million hypothetical members. In the model, NGS saved as much as $2.1 million for Medicare, and more than $250,000 for commercial insurance providers. The study will be presented at the upcoming 2018 ASCO Annual Meeting in Chicago.

"The field of treatment is moving at a rapid pace, and we need to fully characterize genomic changes to determine the best treatment for patients shortly after they are diagnosed," said lead study author Nathan A. Pennell, MD, Ph.D., co-director of the Cleveland Clinic Lung Cancer Program. "Today, many treatment decisions are guided by the presence or absence of certain genetic changes in a patient's tumor, and I expect that several more will be identified in the near future. Therefore, it becomes even more imperative to find a cost-effective gene test that can quickly identify a large number of gene mutations that can be targeted with treatments."

Genetic testing of the tumor is crucial to guide optimal treatment for NSCLC. Many different tests are available today, but there is no accepted standard for when and how the testing should be performed. The authors designed their model to determine which gene testing approach is most cost-effective and time-efficient. The model uses data from the Center for Medicare and Medicaid Services (CMS) and U.S. commercial health plans to estimate costs for each modality.

About the Study

The known genes that are altered in NSCLC includeEGFR, ALK, ROS1, BRAF, MET, HER2, RET,andNTRK1(of those,EGFR, ALK, ROS1,andBRAFcan be targeted with approved treatments). The other genetic changes can be targeted with investigational agents that are being tested in clinical trials. Newer tests also look at PD-L1 expression to predict if a tumor is likely to respond to immunotherapy.

In the model, patients with newly diagnosed metastatic NSCLC received PD-L1 testing and testing for the known lung cancer-related genes using one of four different approaches:

  • Upfront NGS (all eight NSCLC-related genes andKRASwere tested at once)
  • Sequential tests (one gene at a time was tested)
  • ExclusionaryKRAStest, followed by sequential tests for changes in other genes ifKRASwas not mutated (ifKRASmutations were found, the tumor was not tested for other mutations because it is rare to have more than one of these genes mutated in an individual lung cancer)
  • Panel test (combined testing forEGFR, ALK, ROS1,andBRAF), followed by either single-gene or NGS testing for changes in other genes

The model assumed that some participants who did not receive upfront-NGS might need to have another biopsy to test for additional genes (due to insufficient amount of tissue from the first biopsy) and that the need for re-biopsy would be lessened with upfront, comprehensive NGS testing. It also accounted for the time it took to get results back after biopsy samples were sent to the lab, costs for each type of gene testing, and the estimated number of people with metastatic NSCLC in the U.S. that could be tested.

Based on the number and age of people with metastatic NSCLC in the U.S. annually, the researchers estimated that for 1 million-member health plans, 2,066 tests would be paid for by CMS and 156 would be paid for by commercial insurers. The model also estimated that it would take two weeks for the NGS and panel results to be processed, while it would take 4.7 or 4.8 weeks to process the exclusionary and sequential tests, respectively.

Applying economic factors to CMS payments, NGS testing would save about $1.4 million compared to exclusionary testing, over $1.5 million compared to sequential testing, and about $2.1 million compared to panel testing. For commercial health plans, NGS would save $3,809 compared to exclusionary testing and $250,842 compared to panel testing.

A limitation of this study is that it the is based on several assumptions. The authors' next step is to look at actual health systems and evaluate these differences, testing cost-efficiency in a real-world setting.

Explore further: Accurately diagnosing genetic disease prevents cancer, saves lives

Related Stories

Accurately diagnosing genetic disease prevents cancer, saves lives

March 29, 2018
A single, upfront genomic test is more effective for detecting Lynch syndrome in colorectal cancer (CRC) patients than the traditional multiple, sequential testing approach, according to new clinical data reported by The ...

Two studies find resistance mechanisms in ALK+ and ROS1+ cancers

April 11, 2018
Targeted treatments have revolutionized care for lung cancer patients whose tumors harbor ALK or ROS1 alterations. Basically, cancers may use these genetic changes to drive their growth, but also become dependent on the action ...

Testing for EGFR mutations and ALK rearrangements is cost-effective in NSCLC

January 29, 2015
Multiplexed genetic screening for epidermal growth factor receptor (EGFR) and anaplastic lymphoma kinase (ALK) gene rearrangements and subsequent biomarker-guided treatment is cost-effective compared with standard chemotherapy ...

Expert panel issues new guidelines for lung cancer molecular testing

January 30, 2018
Lung cancer treatment often pairs targeted therapies with genetic alterations driving the disease. This makes detecting these genetic alterations an essential step in diagnosis. In 2013, an expert panel made up of members ...

Profiling approach to enable right lung cancer treatment match

May 5, 2015
Manchester researchers have tested a new way to genetically profile lung cancer samples, potentially allowing doctors to more easily identify the most appropriate treatment for patients.

Blood tests at the time of diagnoses of lung cancer may speed up treatment decisions

October 18, 2016
A study from Gundersen Health System, La Crosse, Wisconsin, reveals to the value of blood-based genomic and proteomic testing in patients with lung cancer at the time of initial diagnoses. Non-small cell lung cancer (NSCLC) ...

Recommended for you

Scientists discover how breast cancer hibernates: study

May 22, 2018
Scientists have identified the mechanism that allows breast cancer cells to lie dormant in other parts of the body only to reemerge years later with lethal force, according to a study published Tuesday.

Researcher: Big data, networks identify cell signaling pathways in lung cancer

May 22, 2018
A team of scientists led by University of Montana cell biologist Mark Grimes has identified networks inside lung cancer cells that will help understand this cancer and fight it with drug treatments.

Resetting the epigenetic balance for cancer therapy

May 22, 2018
Though mutations in a gene called MLL3 are common across many types of cancers, their relationship to the development of the disease has been unclear. Now, a Northwestern Medicine study has identified an epigenetic imbalance ...

Downward-facing mouse: Stretching reduces tumor growth in mouse model of breast cancer

May 22, 2018
Many cancer patients seek out gentle, movement-based stretching techniques such as yoga, tai chi and qigong, but does stretching have an effect on cancer? While many animal studies have attempted to quantify the effects of ...

Compound in citrus oil could reduce dry mouth in head, neck cancer patients

May 21, 2018
A compound found in citrus oils could help alleviate dry mouth caused by radiation therapy in head and neck cancer patients, according to a new study by researchers at the Stanford University School of Medicine.

Ice cream funds research showing new strategy against thyroid cancer

May 21, 2018
Anaplastic thyroid cancer is almost uniformly fatal, with an average lifespan of about 5 months after diagnosis. And standard treatment for the condition includes 7 weeks of radiation, often along with chemotherapy.

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.